Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

The generation of a vaccine against HIV-1 able to induce durable protective immunity continues a major challenge. The modest efficacy (31.2%) of the phase III RV144 clinical trial provided the first demonstration that a prophylactic HIV/AIDS vaccine is achievable but emphasized the need for further...

Descripción completa

Detalles Bibliográficos
Autores principales: Perdiguero, Beatriz, Gómez, Carmen Elena, García-Arriaza, Juan, Sánchez-Corzo, Cristina, Sorzano, Carlos Óscar S., Wilmschen, Sarah, von Laer, Dorothee, Asbach, Benedikt, Schmalzl, Christina, Peterhoff, David, Ding, Song, Wagner, Ralf, Kimpel, Janine, Levy, Yves, Pantaleo, Giuseppe, Esteban, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930178/
https://www.ncbi.nlm.nih.gov/pubmed/31921191
http://dx.doi.org/10.3389/fimmu.2019.02941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930178/
https://www.ncbi.nlm.nih.gov/pubmed/31921191
http://dx.doi.org/10.3389/fimmu.2019.02941

Ejemplares similares